Shots:

• Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development- regulatory- & commercialization milestones along with royalties on sales in the territory
• 3D Medicines will get an exclusive right to develop- manufacture- and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions
• Both the companies will share IND development costs. YBL-013 is a T cell bi-specific engager based on ALiCE platform technology and targets CD3 on T cell and PD-L1 on cancer cell

 ­ Ref: PRNasia | Image: Y-Biologics